Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05736952
Other study ID # XH-22-015
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date March 1, 2023
Est. completion date February 1, 2026

Study information

Verified date February 2023
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the treatment of topotecan hydrochloride capsules combined with anlotinib hydrochloride capsules in Patients with platinum-resistant recurrent epithelial ovarian cancer. The main questions it aims to answer are: to assess the objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR), duration of response (DOR), overall survival (OS) and safety of topotecan hydrochloride capsules combined with anlotinib hydrochloride capsules in patients with platinum-resistant recurrent epithelial ovarian cancer.The treatment of participants: Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.;Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment. Receiving optimal supportive care at the same time until disease progression/death/intolerable toxicity.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 1, 2026
Est. primary completion date February 1, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age= 18 years old; 2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2; 3. The pathological type is epithelial ovarian cancer: high-grade serous, clear cell, endometrium-like; or fallopian tube cancer, primary peritoneal cancer; 4. After surgery, the patient received = 2 lines of chemotherapy,Platinum resistant ovarian cancer (defined as relapsing within 6 months after the last administration of platinum-based chemotherapy); 5. Clinical recurrence with measurable lesions (with imaging evidence); 6. Estimated survival= 3 months; 7. The main organs function well, and the examination indicators meet the following requirements: 1) Routine blood test: hemoglobin = 90 g/L (no transfusion within 14 days); Neutrophil count= 1.5×109/L; Platelet count= 80×109/L; 2) Biochemical examination: Total bilirubin =1.5×ULN (upper limit of normal); Blood valley alanine aminotransferase (ALT) or blood valley aminotransferase (AST) = 2.5×ULN; ALT or AST = 5×ULN if liver metastases are present; Serum creatinine = 1.5×ULN or endogenous creatinine clearance = 50 ml/min (Cockcroft-Gault formula); 8. Good compliance, family members agree to cooperate with survival follow-up. Exclusion Criteria: 1. Have other malignant tumors at the same time, except for malignant tumors that have been cured or stabilized; 2. Pregnant or lactating women; 3. Participated in clinical trials of other drugs within six months; 4. Have a variety of factors that affect oral drugs (such as inability to swallow, chronic diarrhea and intestinal obstruction, etc.); 5. Any bleeding event with a severe grade of 3 or above in CTCAE 4.0 within 4 weeks prior to screening; 6. Patients with known central nervous system metastases or history of central nervous system metastases before screening; 7. Patients with hypertension who cannot be well controlled by single antihypertensive drugs (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg); Patients with a history of unstable angina; Patients with a new diagnosis of angina within 3 months before screening or a myocardial infarction event within 6 months before screening; Arrhythmias require long-term use of antiarrhythmic drugs and New York Heart Association grade = II cardiac insufficiency; 8. Long-term unhealed wounds or incompletely healed fractures; 9. Previous organ transplantation history; 10. Imaging shows that the tumor has invaded important blood vessels or the investigator judges that the patient's tumor has a high possibility of invading important blood vessels during treatment and causing fatal hemorrhage; 11. Coagulation dysfunction (prothrombin time>16s, Activated partial thromboplastin>43s, thrombin time>21s, fibrinogen<2g/L), with bleeding tendency (14 days before randomization must meet: INR within normal value without anticoagulant); Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin or their analogues; Under the premise of the international normalized ratio (INR) of prothrombin time (INR) = 1.5, the use of low-dose warfarin (1 mg orally once daily) or low-dose aspirin (not exceeding 100 mg daily) for prophylactic purposes is permitted; 12. Screen for arteriovenous thrombotic events within one year before, such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis (except for venous thrombosis caused by venous catheterization with chemotherapy in the early stage of chemotherapy and judged to have been cured by the investigator) and pulmonary embolism; 13. Those who have a history of psychotropic substance abuse and cannot quit or have mental disorders; 14. Have a history of immunodeficiency, or have other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation; 15. According to the judgment of the investigator, there are serious concomitant diseases that endanger the safety of patients or affect the completion of the study; 16. History of surgical procedures within 28 days; 17. History of abdominal fistula or gastrointestinal perforation within 28 days; 18. Those who may receive other systemic anti-tumor therapy or plan to undergo ovarian cancer debulking surgery during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oral Topotecan Combined With Anlotinib
Topotecan hydrochloride capsules: 2 mg, once daily, oral with dinner for 5 days, discontinued for 16 days, that is, 21 days (3 weeks) as a course of treatment, a total of 6 courses of administration.;Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a course of treatment.

Locations

Country Name City State
China Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (ORR) one year
Secondary progression-free survival (PFS) one year
Secondary disease control rate (DCR) one year
Secondary duration of response (DOR) one year
Secondary overall survival (OS) one year
See also
  Status Clinical Trial Phase
Recruiting NCT05494580 - Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Phase 1/Phase 2
Recruiting NCT05756907 - Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer Phase 1/Phase 2
Recruiting NCT04787289 - A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer Phase 2
Completed NCT04504916 - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002) Phase 2
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Active, not recruiting NCT05979298 - Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer Phase 2
Recruiting NCT04376073 - Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer Phase 2
Not yet recruiting NCT06321484 - Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer Phase 1
Recruiting NCT05271318 - Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. Phase 1
Terminated NCT02575807 - Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer Phase 1/Phase 2
Recruiting NCT06242470 - A Study of MGC026 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05310344 - Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer Phase 2
Active, not recruiting NCT04374630 - Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian Phase 2
Recruiting NCT05551507 - IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer Phase 1/Phase 2
Active, not recruiting NCT03949283 - Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer Phase 3
Not yet recruiting NCT06315491 - A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer Phase 2
Recruiting NCT05870748 - REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Phase 2/Phase 3
Recruiting NCT05198804 - A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Phase 1/Phase 2
Terminated NCT04718376 - A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer Phase 1
Recruiting NCT05081609 - A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies Phase 1/Phase 2